TALS - Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial
- Talaris Therapeutics ( NASDAQ: TALS ) said that its kidney transplant drug, FCR001, was successful in helping patients to wean off chronic anti-rejection drugs in a phase 3 trial .
- In an update, Talaris said that 24 patients have been enrolled in the trial. Three patients who were dosed more than 12 months prior to the data cutoff date have been weaned off all chronic anti-rejection drugs with no evidence of rejection and with stable kidney function.
- In addition, all patients given FCR001 at least three months prior to the data cutoff date have achieved and maintained T-cell chimerism levels >50% at three, six and 12 months after transplant. Chimerism is a condition where both the donor’s and the recipient’s hematopoietic stem cells coexist in the recipient’s bone marrow.
- There were three cases of low-grade acute graft-versus-host disease reported, though all resolved.
- The trial intends to enroll 120 patients total.
- Seeking Alpha's Quant Rating views Talaris ( TALS ) as a hold.
For further details see:
Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial